CRPOF - Ceapro receives approval to begin human trial for anti-inflammatory drug
- Ceapro ( OTCQX:CRPOF ) said on Thursday it had received approval from Health Canada to begin Phase 1/2a study testing its drug, avenanthramide, as a potential anti-inflammatory product.
- This early-stage trial will enroll 96 subjects with dosages that may escalate from 30 mg to 960 mg according to response.
- Recruitment for the trial is expected to begin in early 2023.
For further details see:
Ceapro receives approval to begin human trial for anti-inflammatory drug